The Life and Death of Barn Beetles: Faunas from Manure and Stored Hay inside Farm Buildings in Northern Iceland

This research was funded by the Commonwealth Scholarship Commission and received support from the Research Budget of the Department of Archaeology at the University of Aberdeen. This project was undertaken as part of doctoral studies supervised by Dr Karen Milek, to whom V.F. is especially grateful for her support and advice. Thomas Birch, Sigrún Inga Garðarsdóttir, and Paul Ledger provided invaluable assistance during fieldwork. V.F. would like to dedicate this paper to Tom and Sía, who met during this fieldwork and are getting married this year. Many people from Fornleifastofnun Íslands – Garðar Guðmundsson, Ólöf Þorsteinsdóttir, Þóra Pétursdóttir, Adolf Friðriksson and Uggi Ævarsson – as well as Unnstein Ingason, Ágústa Edwald, and Mark Young, helped with fieldwork logistics. Special thanks are due to all the Icelandic farmers and their families who kindly allowed us to collect insects on their farms and provided help when needed: Hermann Aðalsteinsson, Hermína Fjóla Ingólfsdóttir, Guðmundur Skúlason, Sigrún Á. Franzdóttir, Dúna Magnúsdóttir, Sverrir Steinbergsson, Valgeir Þorvaldsson, Reynir Sveinsson, Jónas Þór Ingólfsson, and Ívar Ólafsson. Eva Panagiotakopulu, Jan Klimaszewski, Ales Smetana, Georges Pelletier, Gabor Pozsgai, and Jenni Stockham helped with some of the beetle identifications. A.J.D. acknowledges the support of National Science Foundation through ARC 1202692. Consultation of the BugsCEP database (Buckland & Buckland, 2006) aided the redaction of this paper. The authors would like to thank David Smith and two anonymous reviewers for insightful comments that helped improve the quality of this paper.Peer reviewedPostprin

Cholinesterase Inhibitors for Alzheimer Disease: Multitargeting Strategy based on Anti-Alzheimer's Drugs Repositioning

International audienceIn the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improvement of AD. Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvementin AD because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibitingperipheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutictarget. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for thesymptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEIs) have been continued to bedeveloped. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper,we summarize the different types of ChEIs which are under development and their respective mechanisms ofactions

Clinical triage of patients on kidney replacement therapy presenting with COVID-19: An ERACODA registry analysis

Background: Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes. Methods: The European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage. Results: Among 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2-7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage. Conclusions: This study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in those with risk factors for poor outcomes. Our findings support a risk-stratified clinical approach to admissions and discharges of KRT patients presenting with COVID-19 to aid clinical triage and optimize resource utilization during the ongoing pandemic. © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved